Literature DB >> 30919324

Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result.

Lesley Stafford1,2, Alison Flehr3, Fiona Judd3,4, Geoffrey J Lindeman5,6, Penny Gibson3, Angela Komiti7, G Bruce Mann8,9, Maira Kentwell6.   

Abstract

The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.

Entities:  

Keywords:  BRCA1/2; Breast/ovarian cancer; Experiences; Genetic testing; Motives; Negative result

Year:  2019        PMID: 30919324      PMCID: PMC6754479          DOI: 10.1007/s12687-019-00415-w

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  34 in total

Review 1.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

2.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning.

Authors:  P A Ganz; J H Rowland; K Desmond; B E Meyerowitz; G E Wyatt
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  The impact of socioeconomic status and race on trial participation for older women with breast cancer.

Authors:  Cary P Gross; Giovanni Filardo; Susan T Mayne; Harlan M Krumholz
Journal:  Cancer       Date:  2005-02-01       Impact factor: 6.860

4.  Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer.

Authors:  B Thewes; B Meiser; I B Hickie
Journal:  Psychooncology       Date:  2001 Nov-Dec       Impact factor: 3.894

5.  Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.

Authors:  Joël Vos; Jan C Oosterwijk; Encarna Gomez-Garcia; Fred H Menko; Margriet J Collee; Christi J van Asperen; Anna M Jansen; Anne M Stiggelbout; Aad Tibben
Journal:  Patient Educ Couns       Date:  2011-12-27

Review 6.  Breast Cancer: Epidemiology and Etiology.

Authors:  ZiQi Tao; Aimin Shi; Cuntao Lu; Tao Song; Zhengguo Zhang; Jing Zhao
Journal:  Cell Biochem Biophys       Date:  2015-06       Impact factor: 2.194

Review 7.  Biomarkers for personalized oncology: recent advances and future challenges.

Authors:  Madhu Kalia
Journal:  Metabolism       Date:  2014-10-30       Impact factor: 8.694

8.  Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review.

Authors:  Jada G Hamilton; Marci Lobel; Anne Moyer
Journal:  Health Psychol       Date:  2009-07       Impact factor: 4.267

Review 9.  Modifiers of risk of hereditary breast and ovarian cancer.

Authors:  Steven A Narod
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

10.  Breast cancer survivors` recollection of their quality of life: Identifying determinants of recall bias in a longitudinal population-based trial.

Authors:  Patricia Lindberg; Petra Netter; Michael Koller; Brunhilde Steinger; Monika Klinkhammer-Schalke
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

View more
  1 in total

1.  Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.

Authors:  Anne Brédart; Jean-Luc Kop; Julia Dick; Alejandra Cano; Antoine De Pauw; Amélie Anota; Joan Brunet; Peter Devilee; Dominique Stoppa-Lyonnet; Rita Schmutzler; Sylvie Dolbeault
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.